About monopar therapeutics inc - MNPR
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
MNPR At a Glance
Monopar Therapeutics, Inc.
1000 Skokie Boulevard
Wilmette, Illinois 60091
| Phone | 1-847-388-0349 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -13,716,894.00 | |
| Sector | Health Technology | Employees | 22 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MNPR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.171 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -20.576 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.00 |
MNPR Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -623,495.182 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
MNPR Liquidity
| Current Ratio | 51.353 |
| Quick Ratio | 51.353 |
| Cash Ratio | 51.33 |
MNPR Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -13.648 |
| Return on Equity | -14.224 |
| Return on Total Capital | -9.941 |
| Return on Invested Capital | -14.213 |
MNPR Capital Structure
| Total Debt to Total Equity | 0.112 |
| Total Debt to Total Capital | 0.112 |
| Total Debt to Total Assets | 0.11 |
| Long-Term Debt to Equity | 0.112 |
| Long-Term Debt to Total Capital | 0.112 |